1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Stroke in 12 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rho-kinase inhibitor (RKI), in the treatment of acute ischemic stroke." | 9.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 7.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 7.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| " To determine if a ROCK mechanism is involved in simvastatin-induced neuroprotection following embolic strokes, we used pharmacological intervention with the ROCK inhibitor, fasudil." | 7.76 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. ( Han, MK; Lapchak, PA, 2010) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 7.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| "A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rho-kinase inhibitor (RKI), in the treatment of acute ischemic stroke." | 5.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 3.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 3.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "We investigated the neuroprotective effects of fasudil's active metabolite, hydroxyfasudil, a Rho-kinase inhibitor, in a rat stroke model in which endothelial damage and subsequent thrombotic occlusion were selectively induced in perforating arteries." | 3.76 | Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. ( Asano, T; Hitomi, A; Ikegaki, I; Iwasaki, M; Kawasaki, K; Mohri, M; Nakazono, O; Satoh, S, 2010) |
| " To determine if a ROCK mechanism is involved in simvastatin-induced neuroprotection following embolic strokes, we used pharmacological intervention with the ROCK inhibitor, fasudil." | 3.76 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. ( Han, MK; Lapchak, PA, 2010) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 3.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| "Hyperlipidemia is a major cardiovascular risk factor associated with progressive cerebrovascular dysfunction and diminished collateral perfusion in stroke." | 1.40 | Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice. ( Ayata, C; Huang, PL; Shin, HK, 2014) |
| "Treatment with fasudil (1 and 10 mg/kg, n=15 each) resulted in a significant improvement in neurological deficits." | 1.31 | A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. ( Asano, T; Ikegaki, I; Satoh, S; Toshima, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Shin, HK | 1 |
| Huang, PL | 1 |
| Ayata, C | 1 |
| Liu, YH | 1 |
| Zhao, Y | 1 |
| Huang, FZ | 1 |
| Chen, YH | 1 |
| Wang, HX | 1 |
| Bonney, E | 1 |
| Liu, BQ | 1 |
| Fukuta, T | 1 |
| Asai, T | 1 |
| Sato, A | 1 |
| Namba, M | 1 |
| Yanagida, Y | 1 |
| Kikuchi, T | 1 |
| Koide, H | 1 |
| Shimizu, K | 1 |
| Oku, N | 1 |
| Feske, SK | 1 |
| Sorond, FA | 1 |
| Henderson, GV | 1 |
| Seto, M | 3 |
| Hitomi, A | 2 |
| Kawasaki, K | 3 |
| Sasaki, Y | 1 |
| Asano, T | 4 |
| Liao, JK | 2 |
| Satoh, S | 3 |
| Ikegaki, I | 3 |
| Nakazono, O | 1 |
| Iwasaki, M | 1 |
| Mohri, M | 1 |
| Lapchak, PA | 1 |
| Han, MK | 1 |
| Ishiguro, M | 1 |
| Suzuki, Y | 1 |
| Ishizuka, F | 1 |
| Mishiro, K | 1 |
| Egashira, Y | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Shibuya, M | 1 |
| Hirai, S | 1 |
| Ohtomo, E | 1 |
| Rikitake, Y | 1 |
| Kim, HH | 1 |
| Huang, Z | 1 |
| Yano, K | 1 |
| Moskowitz, MA | 1 |
| Okamura, N | 1 |
| Saito, M | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Kametaka, S | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Toshima, Y | 1 |
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Stroke
| Article | Year |
|---|---|
Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Aged; Brain Ischemia; Dose-Response Re | 2005 |
11 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Stroke
| Article | Year |
|---|---|
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cerebrovascular Circulation; | 2014 |
Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Brain Infarction; Brai | 2016 |
Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intravenous; Animals; Brain; Brain Is | 2016 |
Increased leukocyte ROCK activity in patients after acute ischemic stroke.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Blotting, Western; Brain Ischemia; Enzyme Inhib | 2009 |
Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Ischemia; Capillary Permeabilit | 2010 |
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anticholesteremic Agents; Brain Infarction; | 2010 |
A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cells, Cultured; Cerebral | 2012 |
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Analysis of Variance; Animals; Antihypertensi | 2005 |
Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Blood Pressure; Dose-R | 2007 |
A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Infarction; Carotid Artery, Internal; | 2000 |